Skip to main content
SpringerLink
Log in

A Fair Innings for NICE?

  • Commentary
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ginsberg G, Lowe S. Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature. Pharmacoeconomics 2002; 20: 367–87

    Article  PubMed  CAS  Google Scholar 

  2. National Institute for Clinical Excellence (NICE). Guidance on the use of riluzole (rilutek) for the treatment of motor neurone disease. London: NICE, 2001

    Google Scholar 

  3. Freemantle N. Interpreting the results of secondary endpoints and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? BMJ 2001; 322: 989–91

    Article  PubMed  CAS  Google Scholar 

  4. Aventis Pharmaceuticals. Rilutek tablets. Product Monograph [online]. New Jersey, Aventis Pharmaceuticals. In: PDR Electronic Library ver 5.2.0a, New Jersey: Medical Economics Company, 2001

    Google Scholar 

  5. Stewart A, Sandercock J, Bryan S, et al. The clinical effectiveness and cost effectiveness of riluzole for motor neurone disease. Edgbaston: West Midlands Development and Evaluation Service, Department of Public Health and Epidemiology, University of Birmingham, Aug 2000

    Google Scholar 

  6. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996

    Google Scholar 

  7. FDA approves first drug for Lou Gehrig’s disease [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/NEW00522.html [Accessed 2001, Nov 2]

  8. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716–22

    Article  Google Scholar 

  9. Williams A. Intergenerational equity: an exploration of the fair innings argument. Health Econ 1997; 6: 117–32

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Nick Freemantle has undertaken research and consultancy for Aventis Pharmaceuticals, and the Department of Health in England.

Author information

Authors and Affiliations

  1. Department of Primary Care and General Practice, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

    Nick Freemantle & Joanne Eastaugh

  2. Department of Health Sciences and Clinical Evaluation, University of York, York, UK

    Karen Bloor

Authors
  1. Nick Freemantle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen Bloor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joanne Eastaugh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nick Freemantle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Freemantle, N., Bloor, K. & Eastaugh, J. A Fair Innings for NICE?. Pharmacoeconomics 20, 389–391 (2002). https://doi.org/10.2165/00019053-200220060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200220060-00003

Keywords

Search

Navigation